|
Market Cap (6-Jul) TBC |
Close (30-Jun) $0.059 |
Volume (30-Jun) 4,352,698 |
Shortsold (24-Jul) 256 (0.00%) (719th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS - |
ANP released this announcement to the ASX on 28 July 2021, 9:06. The announcement is not marked as price sensitive, and is 2 page(s) in length and 185.07kb in size.
You can view all announcements from ANP and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANP was 0.021% short sold according to ASIC data. It was ranked the 587th most shorted stock on the ASX. It remains ranked 719th as of the latest reported data (24 July 2023).
| Other Recent Announcements from ANP | |
|---|---|
| MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK | 27 June 2023, 15:46 |
| First Patient Dosed in ATL1102 Phase IIb DMD Trial | 8 June 2023, 8:38 |
| Shareholder Newsletter | 6 June 2023, 15:47 |
| Antisense Therapeutics transitions to new Board Chair | 28 July 2021, 9:06 |
| ANP and MCRI new R&D collaboration for ATL1102 | 28 June 2021, 9:56 |
| ATL1102 for DMD EMA PIP feedback and FDA regulatory progress | 22 June 2021, 9:09 |
| US FDA Feedback on Type C Meeting for ATL1102 in the US | 1 June 2021, 9:58 |
You must be logged in to post a reply.
Antisense Therapeutics 